StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. (ROIV) KPIs and segments

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.73+0.02 (+0.05%)

Close on Nov 18, 2026Market cap $27.98BP/E –Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Roivant Sciences · năm tài chính kết thúc ngày 31 tháng 3

Nhìn nhanh KPI của Roivant Sciences: 54 chỉ số vận hành, trong đó có Cumulative Vant-Sponsored Clinical Studies, Cumulative Clinical Trial Patient Enrollment và Immunovant, Inc. — Basic Ownership Stake, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Roivant Sciences kết thúc ngày 31 tháng 3 — Q2 FY2026 = CQ3 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 FY2026
Q1 FY2026
Q4 FY2025
Q3 FY2025
Q2 FY2025
Q1 FY2025
Q4 FY2024
Q3 FY2024
Q2 FY2024
Q1 FY2024
Q4 FY2023
Q3 FY2023
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Cumulative Vant-Sponsored Clinical Studies9
373636343332272422202020
Phase 3 Registrational Studies
1099888666555
Phase 2 Clinical Studies
242424232221191614131313
Phase 1 Clinical Studies
333333222222
Immunovant — Total Anti-FcRn Studies2
191919181817141110101010
IMVT-1402 (Imeroprubart) Studies
888777410000
Batoclimab (IMVT-1401) Studies
111111111110101010101010
Priovant — Brepocitinib (LISRAYA) Studies
666555444222
Pulmovant — Mosliciguat Studies
433322110000
Kinevant — Namilumab & Gimsilumab Studies
444444444444
Dermavant — Tapinarof & Cerdulatinib Studies (Legacy)
444444444444
New Vant-Sponsored Studies Initiated
102115322000
Cumulative Clinical Trial Patient Enrollment9
4,7464,3704,3703,6563,6363,6102,8132,4752,1001,7241,7241,724
Phase 3 Patient Enrollment
2,2711,8951,8951,5531,5531,5531,1541,1541,154783783783
Phase 2 Patient Enrollment
2,4072,4072,4072,0352,0151,9891,5991,261886881881881
Phase 1 Patient Enrollment
686868686868606060606060
Immunovant — Total Anti-FcRn Patient Enrollment2
2,3592,3592,3591,9871,9871,9611,3401,002762762762762
IMVT-1402 (Imeroprubart) Patient Enrollment
1,5711,5711,5711,1991,1991,1995782400000
Batoclimab (IMVT-1401) Patient Enrollment
788788788788788762762762762762762762
Priovant — Brepocitinib (LISRAYA) Patient Enrollment
1,1531,1531,153811811811643643643267267267
Pulmovant — Mosliciguat Patient Enrollment
5391631631631431431351350000
Kinevant — Namilumab & Gimsilumab Patient Enrollment
371371371371371371371371371371371371
Dermavant — Clinical Trial Patient Enrollment (Legacy)
324324324324324324324324324324324324
New Patient Enrollment Added in Initiated Trials
37607142026797338375376000
Immunovant, Inc. — Basic Ownership Stake(%)1
55.0%55.0%56.0%56.0%55.0%55.0%55.0%55.0%
Immunovant, Inc. — Fully Diluted Ownership Stake(%)
52.0%52.0%52.0%52.0%50.0%48.0%49.0%49.0%
Priovant Therapeutics — Basic Ownership Stake(%)1
71.0%71.0%72.0%73.0%73.0%75.0%75.0%75.0%
Priovant Therapeutics — Fully Diluted Ownership Stake(%)
65.0%65.0%66.0%66.0%65.0%67.0%68.0%68.0%
Pulmovant, Inc. — Basic Ownership Stake(%)1
95.0%97.0%97.0%98.0%98.0%
Pulmovant, Inc. — Fully Diluted Ownership Stake(%)
90.0%90.0%90.0%91.0%91.0%
Genevant Sciences Ltd. — Basic Ownership Stake(%)1
83.0%83.0%83.0%83.0%83.0%83.0%83.0%83.0%
Genevant Sciences Ltd. — Fully Diluted Ownership Stake(%)
64.0%64.0%64.0%64.0%64.0%65.0%65.0%65.0%
Covant Therapeutics — Basic Ownership Stake(%)1
96.0%96.0%94.0%95.0%95.0%100.0%100.0%100.0%
Covant Therapeutics — Fully Diluted Ownership Stake(%)
90.0%91.0%91.0%91.0%90.0%87.0%87.0%86.0%
Arbutus Biopharma Corp. — Basic Ownership Stake(%)5
19.0%20.0%20.0%20.0%20.0%21.0%22.0%23.0%
Arbutus Biopharma Corp. — Fully Diluted Ownership Stake(%)
19.0%19.0%19.0%19.0%19.0%19.0%19.0%20.0%
Arbutus Biopharma — Exact Voting Ownership Stake (Footnote XBRL)(%)
19.0%20.0%20.0%20.0%20.0%20.0%20.0%20.0%21.0%21.0%22.0%23.0%
Arbutus Biopharma — Investment Fair Value (Level 1)($M)
18618717518717612013612715012010097.1
Arbutus Biopharma — Unrealized Gain (Loss) on Investment($M)
-0.8011.7-90.510.556.3-15.5-62.2-22.529.519.838.118.3
Arbutus Biopharma — Period-End Common Share Price($)
4.784.804.504.814.543.093.493.273.853.092.582.50
Datavant Holdings — Minority Equity Ownership Stake(%)2
9.0%9.0%9.0%9.0%9.0%9.0%9.0%9.0%9.0%9.0%9.0%9.0%
Datavant Holdings — Investment Fair Value (Level 3)($M)
319258233247236164167163162143148136
Datavant Holdings — Gain (Loss) on Investment($M)
61.125-14611.172.2-3.60-35.31.2018.94.6073.7-28.4
Dermavant Sciences — Basic Ownership Stake (Legacy, Divested Q2 FY2024)(%)1
87.0%100.0%100.0%
Dermavant Sciences — Fully Diluted Ownership Stake (Legacy)(%)
82.0%86.0%85.0%
Kinevant Sciences — Basic Ownership Stake (Legacy)(%)1
96.0%96.0%96.0%
Lokavant — Basic Ownership Stake (Legacy)(%)1
57.0%57.0%57.0%
Psivant Therapeutics — Basic Ownership Stake (Legacy)(%)1
48.0%48.0%100.0%
Total Program-Specific R&D Expense($M)12
96.813995.110389.783.890.077.167.8
Anti-FcRn Franchise — Endocrine Diseases R&D($M)
22.542.926.319.824.919.316.815.514.915.96.88
Anti-FcRn Franchise — Neurological Diseases R&D($M)
18.325.520.817.723.120.920.225.029.618.512.8
Anti-FcRn Franchise — Rheumatology Diseases R&D($M)
9.9022.312.914.113.68.206.708.20900
Anti-FcRn Franchise — Dermatology Diseases R&D($M)
0.607.504.10385.105.7054.900
Anti-FcRn Franchise — Other Clinical & Nonclinical R&D($M)
0.272.610.190.460.322.391.750.041.136.404.89
Brepocitinib (LISRAYA) Program R&D($M)
14.414.114.316.214.715.013.110.910.510.610.4
Mosliciguat Program R&D($M)
19.113.09.8310.47.478.395.884.706.182.982.01
Other Development & Discovery Programs R&D($M)
11.811.113.413.411.210.214.014.613.715.512.3
Tapinarof (VTAMA) Program R&D (Legacy, Divested FY2024)($M)
6.968.78
RVT-3101 (Telavant) Program R&D (Legacy, Divested FY2023)($M)
0005.65
Namilumab Program R&D (Legacy)($M)
3.133.494.383.28
RVT-2001 Program R&D (Legacy)($M)
0.030.221.661.90
Unallocated R&D — Personnel-Related Expenses($M)2
33.346.441.440.742.538.333.635.237.6
Unallocated R&D — Share-Based Compensation($M)
7.978.727.6518.111.011.19.659.699.9110.59.766.91
Unallocated R&D — Other Internal Expenses($M)
7.707.8610.79.689.649.799.589.9710.8
SG&A — Share-Based Compensation Expense($M)2
71.374.669.586.970.871.173.869.459.436.834.044.4
SG&A — Personnel-Related Expenses($M)
38.856.228.238.030.133.611029.7
SG&A — Other Operating & Commercial Launch Expenses($M)
44.034.760.034.332.838.633.633.4
Adjusted R&D Expense (Non-GAAP)($M)
137193191147153141135131132122115
Adjusted SG&A Expense (Non-GAAP)($M)
82.590.788.571.072.162.672.371.1142108148
Adjusted Net Loss from Continuing Operations (Non-GAAP)($M)
-133-244-223-167-188-170-154-144-219-131-175
Litigation Settlement Gain (Moderna Global LNP Settlement)($M)1
00.4000
Litigation Settlement Receivable, Current($M)
07727700
Immunovant — Total Standalone R&D Expense($M)3
85.014398.911410194.597.375.548.3
Immunovant — Total Therapeutic Area-Specific R&D($M)5
51.510155.169.956.053.659.640.824.6
Endocrine Diseases R&D (Graves' Disease & TED)($M)
22.542.919.824.919.315.514.915.96.88
Neurological Diseases R&D (MG & CIDP)($M)
18.325.517.723.120.925.029.618.512.8
Rheumatology Diseases R&D (D2T RA & SjD)($M)
9.8622.314.113.68.218.189.0500
Dermatology Diseases R&D (CLE)($M)
0.657.543.047.955.154.954.940
Other Clinical & Nonclinical R&D($M)
0.272.610.460.322.390.041.136.404.89
Immunovant — Unallocated Personnel-Related & SBC R&D($M)
24.133.532.232.634.529.526.324.517.3
Immunovant — Unallocated Other R&D($M)
9.408.3011.611.710.711.411.310.26.47
Immunovant — Standalone G&A Expense($M)
19.117.717.315.417.52620.219.818.518.814.813.2
Immunovant — Total Standalone Operating Expenses($M)
10416016011413212711411411694.380.961.6
Immunovant — Standalone Share-Based Compensation($M)
13.313.811.112.713.418.511.711.712.713.59.7010.2
Immunovant — Standalone Net Loss($M)
-97.2-153-148-111-127-121-106-111-109-87.2-75.3-51.4
Immunovant — Operating Cash Flow($M)
-83.2-124-95.1-92.3-103-117-111-100-88.6-76.2-59.7-47.1
Immunovant — Standalone Cash & Cash Equivalents($M)2
722798902995522599714375473560635691
Immunovant — Accrued Professional & Clinical Fees($M)
1.300.701.301.300.900.800.800.100.300.500.500.20
Immunovant — Accrued Employee Bonuses($M)
7.305.3016.814.19.504.9015.611.37.103.4014.77.50
Immunovant — Common Shares Outstanding(M)8
207206204203175171170147147146146145
Immunovant — Stock Options Outstanding(M)
7.948.369.9910.612.914.813.013.213.614.013.013.1
Immunovant — Stock Options Exercisable(M)
4.394.424.885.016.759.629.439.128.988.507.526.97
Immunovant — Stock Options Granted(M)
0.061.070.020.071.552.840.020.341.140.250.07
Immunovant — Stock Options Exercised(M)
0.331.650.392.123.200.430.150.330.060.150.31
Immunovant — Options Weighted-Average Exercise Price($)
16.4116.4515.2215.0714.2312.621211.9711.5611.509.859.36
Immunovant — Options Aggregate Intrinsic Value($M)
13918510411748.173.889179235217294429
Immunovant — Equity Plan Shares Available for Future Grant(M)
6.756.587.827.637.388.596.035.946.055.682.092.18
Immunovant — Antidilutive Securities Excluded from Diluted EPS(M)
11.712.513.614.517.219.516.216.817.318.116.516.9
Common Shares Repurchased & Retired(M)4
2.476.893.960020.3020.89.0271.3
Share Repurchase Aggregate Cost($M)
72.5209110002080243106648
Remaining Share Repurchase Authorization($M)
609682890500500
At-the-Market (ATM) Equity Facility Remaining Capacity($M)
400400400400400400400400400400400400
Tax Withholding & Excise Payments on Equity Settlements/Repurchases($M)
21.151.48.8023.96.509.507.508.608.5012.728.63.30
Common Shares Outstanding (Filing Cover Date)(M)1
725722719716695683680714728740739806
Common Shares Outstanding (Period-End Balance Sheet)(M)
724723720710690682696720733739807805
Antidilutive Securities — Stock Options & Performance Options(M)7
68.171.076.197.412913613914214854.754.765.5
Antidilutive — Restricted Stock Units & Performance Stock Units(M)
59.860.360.863.765.753.151.051.552.05.425.425.42
Antidilutive — Nonvested Earn-Out Shares(M)
00003.083.083.083.083.083.083.083.08
Antidilutive — March 2020 Capped Value Appreciation Rights (CVARs)(M)
00017.617.617.617.617.617.617.617.617.6
Antidilutive — Other Stock-Based Awards & Instruments(M)
0.390.421.173.674.064.494.735.035.033.923.924.15
Antidilutive — November 2021 CVARs (Legacy)(M)
00000.350.711.070.200.250.36
Antidilutive — Public Warrants (Legacy, Redeemed FY2024)(M)
000
Antidilutive — Private Placement Warrants (Legacy, Redeemed FY2024)(M)
000
Marketable Debt Securities — Total Fair Value($M)9
2,5652,5942,8732,7891,8032,172
Marketable Debt Securities — Total Amortized Cost($M)
2,5822,6002,876
Marketable Debt Securities — Gross Unrealized Gains($M)
0.030.030.54
Marketable Debt Securities — Gross Unrealized Losses($M)
16.36.574.09
U.S. Treasury Securities — Fair Value($M)3
1,8791,8892,1243,0523,1493,2640
U.S. Treasury Securities — Amortized Cost($M)
1,8911,8922,1253,0483,1463,2642,172
U.S. Treasury Securities — Gross Unrealized Gains($M)
00.030.543.923.140.861.27
U.S. Treasury Securities — Gross Unrealized Losses($M)
11.93.711.4100.070.790.46
Corporate Debt Securities — Fair Value($M)3
6687057480
Corporate Debt Securities — Amortized Cost($M)
673708751
Corporate Debt Securities — Gross Unrealized Gains($M)
0.0300
Corporate Debt Securities — Gross Unrealized Losses($M)
4.362.862.68
Cash Equivalents — Money Market Funds (Level 1)($M)
1,4761,1711,3751,3861,1352,622
Marketable Debt Securities — Contractual Maturities Within 1 Year($M)
1,4521,6452,145
Marketable Debt Securities — Contractual Maturities 1 to 5 Years($M)
1,114949727
Net Accretion of Discounts on Marketable Securities($M)
4.905.706.400.90
Financial Assets Measured at Fair Value — Total($M)4
4,5464,2104,6554,8722,924
Fair Value Hierarchy — Level 1 Financial Assets($M)
1,6611,3581,5501,5732,757
Fair Value Hierarchy — Level 2 Financial Assets($M)
2,5652,5942,8733,0520
Fair Value Hierarchy — Level 3 Financial Assets($M)
319258233247167
Financial Liabilities Measured at Fair Value — Total($M)
000
Cash, Cash Equivalents & Restricted Cash($M)3
1,6501,2611,4311,4891,2471,2492,7262,0021,9705,6936,5066,686
Restricted Cash — Current($M)
04.203.862.612.262.262.363.103.115.413.075.17
Restricted Cash — Non-Current($M)
7.327.897.897.897.897.897.897.898.179.388.179.48
Accrued Interest Receivable($M)
21.621.619.612.123.213.922.727.418.9
Share-Based Compensation — Subsidiary Equity Incentive Plans($M)7
1414.811.338.414.419.31413.513.914.71120.2
Subsidiary Share-Based Awards Vested & Exercised (Equity Impact)($M)
6.4023.621.625.13.602.600.800.70
Cash Proceeds from Stock Option Exercises($M)
25.476.051.211968.330.112.628.16.622.273.298.88
Roivant Stock Options Outstanding (RSL Plans)(M)
68.171.076.197.4129136139142148150147
Roivant Stock Options Exercisable (RSL Plans)(M)
63.565.569.6111111107108105
Unvested Restricted Stock Units (RSL Equity Plans)(M)
11.612.112.60000.350.711.071.431.78
Unvested Performance Stock Units (RSL Equity Plans)(M)
48.248.248.248.848.836.936.95.42
Forfeited Performance Stock Units (RSL Equity Plans)(M)
000.580
Total Accrued Current Liabilities($M)5
18816920611810888.7114104112138119122
Accrued Clinical Trial & R&D Expenses($M)
10611392.755.758.949.845.853.556.346.537.743.6
Accrued Employee Compensation & Benefits($M)
55.640.887.338.126.426.553.939.338.837.849.941.4
Other Accrued Current Liabilities($M)
26.314.525.724.22312.414.611.616.326.331.820.3
Income Taxes Payable — Current($M)
59.174.245.77.170.420.585.4123.49.7725.2
Income Taxes Payable — Non-Current($M)
0038.70
Operating Lease Right-of-Use (ROU) Assets($M)3
77.378.980.483.685.187.18990.94345.34446.9
Operating Lease Liabilities — Current($M)
13.812.411.110.499.409.809.809.509.50910.5
Operating Lease Liabilities — Non-Current($M)
92.894.896.398.589.890.390.390.543.245.94547.1
Operating Lease ROU Asset Amortization($M)
1.541.391.862.531.941.941.971.711.581.581.801.73
Gross Deferred Tax Assets1
Effective Income Tax Rate (Continuing Operations)(%)
3.8%1.3%-50.4%-4.9%-2.7%-1.7%-7.1%0.2%-10.0%-60.9%0.5%0.6%
Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue($M)7
0.301.011790.5310.71.761.341.731.53
Arbutus Biopharma Corp. (ABUS) — R&D Expense($M)
2.622.904.125.785.508.9614.315.615.4
Arbutus Biopharma Corp. (ABUS) — G&A Expense($M)
7.963.875.893.043.335.834.547.555.31
Arbutus Biopharma Corp. (ABUS) — Net Income (Loss)($M)
59.1-5.14170-7.742.52-24.5-19.7-19.8-17.9
Arbutus Biopharma Corp. (ABUS) — Cash & Cash Equivalents($M)
26419.223.718.022.437.437.136.331.962.843.126.3
Arbutus Biopharma Corp. (ABUS) — Marketable Securities($M)
73.373.571.573.571.360.775.686.396.079.286.199.7
Arbutus Biopharma Corp. (ABUS) — Common Shares Outstanding(M)
199198197193192192191190189189180170
Arbutus Biopharma Corp. (ABUS) — Antidilutive Securities(M)
8.249.1410.41414.414.015.616.922.620.4
U.S. Real PCE: Pharmaceutical & Other Medical Products (SAAR)($M)
3,858,6703,790,2903,699,9003,666,9903,614,8503,529,8303,464,6503,417,8303,358,2403,288,2203,244,3603,159,380
Consolidated Revenue, Net($M)11
35.11.402.5021.602.207.6094.508915.6
Consolidated R&D Expense (GAAP)($M)
146202199165165153145142143121108108
Consolidated SG&A Expense (GAAP)($M)
154166158175143134147142203149170197
Operating Income (Loss) (GAAP)($M)
-268-366415-339-306-285-285-274-342-102-2075,128
Interest Income($M)
41.636.941.243.345.348.354.661.969.8
Change in Fair Value / Gain on Investments($M)
60.336.6-25.921.6129-19.112.9-21.348.415.215.9-10.5
Income (Loss) from Continuing Operations($M)
-207-291303-266-114-274-207-158-1876-645,155
Income (Loss) from Discontinued Operations, Net of Tax($M)
15.800000327-43.189.1-87.5-58.5
Net Income (Loss) Attributable to Noncontrolling Interests($M)
54.4-10152.8-47.8-52.5-50.6-45.9-51.3-49.7-37.8-31.4-23.5
Net Income (Loss) Attributable to Roivant Sciences Ltd.($M)
-192-190303-266-114-223-207169-23095.3-1515,096
Diluted Earnings (Loss) Per Share($)
-0.27-0.26-0.38-0.17-0.330.23-0.310.126.03
Weighted-Average Diluted Shares(M)
723721697681680723735782844
Cash, Cash Equivalents & Short-Term Investments($M)8
4,2083,8424,2924,5304,3864,5034,8875,1475,3876,495
Cash & Cash Equivalents($M)
1,6421,2491,4191,4781,2371,2392,7151,9911,9595,6796,4956,671
Short-Term Marketable Securities($M)
2,5652,5942,8733,0523,1493,2652,1723,1563,4280
Property, Plant & Equipment, Net($M)
10.911.31213.425.714.912.113.613.717.815.321.9
Total Assets($M)
4,9765,3075,7095,2255,0635,0335,4375,7926,2066,4967,2237,313
Total Liabilities($M)
380385416251257217250256626601774728
Shareholders' Equity Attributable to Roivant Sciences Ltd.($M)
4,0204,2314,5274,2694,3624,3464,6885,1905,1535,4355,9696,090
Noncontrolling Interests (Balance Sheet)($M)
575691765705443470500347427460480495
Total Shareholders' Equity($M)
4,5964,9225,2924,9744,8064,8165,1875,5365,5805,8956,4496,585
Operating Cash Flow($M)4
594-271-164-197-186-204-173-207-267-193-109-211
Capital Expenditures($M)
0.210.421.26-4.937.854.040.811.8310.960.350.35
Share-Based Compensation (Cash Flow)($M)
79.383.377.210581.882.283.583.771.750.246.754.3
Investing Cash Flow($M)
42.5281174110120-1,0861,074454-3,294-16.905,233
Financing Cash Flow($M)
-249-182-68.832862.6-188-177-273-109-661-32.6237

4 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & Vant operating structure: Roivant Sciences Ltd. (NASDAQ: ROIV, CIK 0001635088) ends its fiscal year on March 31 and names each fiscal year after the calendar year in which it begins (FY2025 = April 1, 2025 through March 31, 2026; Q1 FY2026 ended June 30, 2026; Q2 FY2026 ended September 30, 2026). Roivant develops and commercializes medicines through focused operating subsidiaries ('Vants'), led by Priovant Therapeutics (LISRAYA / brepocitinib, FDA-approved in August 2026 for adult dermatomyositis), Immunovant, Inc. (NASDAQ: IMVT — anti-FcRn antibodies IMVT-1402 / imeroprubart and batoclimab), Pulmovant, Inc. (mosliciguat in PH-ILD), and Genevant Sciences Ltd. (LNP delivery platform & mRNA patent portfolio).
  • Core operational & R&D metrics (Groups 1–3) track: (1) Clinical Trial Pipeline & Patient Enrollment across 37 Vant-sponsored clinical studies and 4,746 cumulative enrolled/target patients registered on ClinicalTrials.gov through Q2 FY2026, disaggregated by clinical phase and by Vant/molecule; (2) Roivant's Basic and Fully Diluted percentage equity ownership across each active and legacy Vant alongside fair value and ownership stakes in equity-method affiliates Arbutus Biopharma Corp. and Datavant Holdings; and (3) Program-specific R&D investment across five Anti-FcRn therapeutic areas, brepocitinib, mosliciguat, and discovery programs, unallocated personnel and share-based compensation, Non-GAAP Adjusted R&D and SG&A reconciliations, LISRAYA commercial launch net product revenue ($31.0M in Q2 FY2026), and Genevant's Moderna global LNP litigation settlement.
  • Subsidiary, capital allocation & benchmark metrics (Groups 4–8) present: (4) Standalone SEC disclosures of publicly traded consolidated subsidiary Immunovant, Inc. (CIK 0001764013, ~55% basic / 52% diluted ownership), including therapeutic-area R&D, $722.3M standalone cash, stock option rollforwards, and 315 full-time employees; (5) Share repurchase execution across 10 consecutive quarters (128.4M shares for $1,293.2M in FY2024; 24.2M shares for $318.1M in FY2025; 9.4M shares for $281.2M in 6M FY2026 with $609.3M remaining authorization), $2,565.3M marketable debt securities portfolio by instrument and maturity, and antidilutive securities; (6) Subsidiary equity plan SBC, accrued clinical liabilities, operating leases, deferred tax attributes ($541M+ gross DTA), consolidated workforce (721 full-time employees), and DEF 14A Pay Versus Performance; (7) Standalone quarterly results of affiliate Arbutus Biopharma Corp. (CIK 0001447028) and U.S. pharmaceutical macro benchmarks from FRED; and (8) Consolidated GAAP financial context.
  • Methodology: Under U.S. GAAP, Roivant Sciences Ltd. (a Bermuda holding company) does not publish quarterly parent-only operating financial statements, so no Consolidated − Parent Standalone subtraction is performed; instead, standalone filings of publicly traded subsidiary Immunovant, Inc. (IMVT) and affiliate Arbutus Biopharma Corp. (ABUS) are reported directly. All figures are strictly as published, except period-splitting derivations (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M) shown in italic with their exact formula.

Không hiện vì thiếu các kỳ gần đây (10)

  • LISRAYA (brepocitinib) commercial net product revenue ($31.0M in Q2 FY2026), License, milestone and other revenue disaggregation ($4.2M in Q2 FY2026), commercial cost of revenues ($3.3M in Q2 FY2026), commercial inventory ($12.1M at Q2 FY2026), specialty pharmacy customer concentration (82% Customer A and 18% Customer B in Q2 FY2026), and launch callouts ('hundreds of patients on paid drug', 'many hundreds of active prescribers'): following Dermavant's divestiture in Q2 FY2024, Roivant had no continuing commercial product until FDA approval of LISRAYA in late August 2026 (5 weeks before Q2 FY2026 quarter-end), leaving disaggregated commercial product lines with only 1 active post-launch quarter (omitted in Q4 FY2025 and Q1 FY2026 filings), fewer than the required 3 consecutive quarters; consolidated net revenue ($35.1M in Q2 FY2026) is included in Group 8.
  • Anti-FcRn franchise contractual costs related to batoclimab program discontinuation ($39.0M in FY2025 vs. $0 in FY2024 and FY2023): one-time FY2025 charge without recurring quarterly series through Q2 FY2026.
  • Early-stage divested or wound-down Vants with fewer than 3 recent periods or discontinued pre-FY2023 without recurring updates (Alyvant, Aruvant, Cytovant, Lysovant, Sio Gene Therapies, Affivant, Hemavant, VantAI): excluded or superseded as Roivant consolidated its active clinical portfolio around Priovant, Immunovant, Pulmovant, and Genevant.
  • Clinical trial efficacy & biomarker readouts (IMVT-1402 D2T RA ACR20/50/70 response rates, CLARITY-1/2 NIU treatment failure hazard ratios & steroid-free quiescence %, PHocus mosliciguat PVR reduction & 6MWD meters, VALOR DM TIS scores) and epidemiological prevalence estimates (~85,000 U.S. D2T RA, 70,000–190,000 U.S. NIU, ~40,000 CS, ~100,000 LPP): cohort-specific trial endpoints or static disease prevalence constants rather than periodic operating time series.
  • One-time M&A and litigation deal parameters: Organon Dermavant transaction milestones (up to $1.2B total: $175M upfront, $75M AD approval milestone, up to $950M commercial milestones, 30% royalty above $1B sales starting 2027), Roche Telavant $7.1B upfront + $150M milestone parameters, and Moderna $1.3B contingent Section 1498 appellate tranche.
  • Approximate / bound-only disclosures ('hundreds of patients on paid drug', 'over 275,000 patients treated', 'more than 2,000 subjects', 'up to $1.0 billion', 'up to 300,000 patients'): excluded because bound expressions are not exact point observations.
  • External Peer Affiliate & U.S. Pharmaceutical Macro Benchmarks › Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue › Arbutus Biopharma Corp. (ABUS) — Share-Based Compensation
  • External Peer Affiliate & U.S. Pharmaceutical Macro Benchmarks › Arbutus Biopharma Corp. (ABUS) — Collaboration & License Revenue › Arbutus Biopharma Corp. (ABUS) — Operating Cash Flow
  • Consolidated GAAP Financial Context › Cash, Cash Equivalents & Short-Term Investments › Long-Term Investments
  • Consolidated GAAP Financial Context › Operating Cash Flow › Cash Paid for Share Repurchases

Dữ liệu cập nhật 2026-11-16.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Roivant Sciences

See a number that looks wrong?